|
Gene: SURF2 |
Gene summary for SURF2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | SURF2 | Gene ID | 6835 |
Gene name | surfeit 2 | |
Gene Alias | SURF-2 | |
Cytomap | 9q34.2 | |
Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | Q15527 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
6835 | SURF2 | LZE2D | Human | Esophagus | HGIN | 4.43e-02 | 2.16e-01 | 0.0642 |
6835 | SURF2 | LZE4T | Human | Esophagus | ESCC | 5.83e-11 | 4.48e-01 | 0.0811 |
6835 | SURF2 | LZE7T | Human | Esophagus | ESCC | 3.96e-12 | 5.40e-01 | 0.0667 |
6835 | SURF2 | LZE8T | Human | Esophagus | ESCC | 7.82e-09 | 1.48e-01 | 0.067 |
6835 | SURF2 | LZE20T | Human | Esophagus | ESCC | 8.44e-10 | 5.11e-01 | 0.0662 |
6835 | SURF2 | LZE24T | Human | Esophagus | ESCC | 4.77e-19 | 6.02e-01 | 0.0596 |
6835 | SURF2 | LZE21T | Human | Esophagus | ESCC | 1.31e-02 | 5.33e-01 | 0.0655 |
6835 | SURF2 | LZE6T | Human | Esophagus | ESCC | 2.63e-05 | 4.23e-01 | 0.0845 |
6835 | SURF2 | P1T-E | Human | Esophagus | ESCC | 8.32e-09 | 2.76e-01 | 0.0875 |
6835 | SURF2 | P2T-E | Human | Esophagus | ESCC | 3.27e-46 | 8.86e-01 | 0.1177 |
6835 | SURF2 | P4T-E | Human | Esophagus | ESCC | 1.90e-40 | 1.09e+00 | 0.1323 |
6835 | SURF2 | P5T-E | Human | Esophagus | ESCC | 2.55e-46 | 9.46e-01 | 0.1327 |
6835 | SURF2 | P8T-E | Human | Esophagus | ESCC | 4.38e-23 | 4.47e-01 | 0.0889 |
6835 | SURF2 | P9T-E | Human | Esophagus | ESCC | 1.73e-22 | 6.05e-01 | 0.1131 |
6835 | SURF2 | P10T-E | Human | Esophagus | ESCC | 4.36e-22 | 3.96e-01 | 0.116 |
6835 | SURF2 | P11T-E | Human | Esophagus | ESCC | 3.95e-13 | 5.99e-01 | 0.1426 |
6835 | SURF2 | P12T-E | Human | Esophagus | ESCC | 9.85e-30 | 5.12e-01 | 0.1122 |
6835 | SURF2 | P15T-E | Human | Esophagus | ESCC | 3.35e-30 | 7.17e-01 | 0.1149 |
6835 | SURF2 | P16T-E | Human | Esophagus | ESCC | 1.27e-27 | 5.22e-01 | 0.1153 |
6835 | SURF2 | P17T-E | Human | Esophagus | ESCC | 1.58e-17 | 7.78e-01 | 0.1278 |
Page: 1 2 3 4 5 6 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SURF2 | SNV | Missense_Mutation | c.479N>T | p.Gly160Val | p.G160V | Q15527 | protein_coding | deleterious(0.01) | possibly_damaging(0.784) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
SURF2 | SNV | Missense_Mutation | novel | c.103G>C | p.Glu35Gln | p.E35Q | Q15527 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
SURF2 | SNV | Missense_Mutation | novel | c.592N>C | p.Glu198Gln | p.E198Q | Q15527 | protein_coding | deleterious(0.03) | benign(0.273) | TCGA-MA-AA41-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
SURF2 | SNV | Missense_Mutation | c.433C>T | p.Arg145Cys | p.R145C | Q15527 | protein_coding | tolerated(0.18) | benign(0.02) | TCGA-VS-A9V5-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD | |
SURF2 | SNV | Missense_Mutation | rs782078411 | c.262N>T | p.Arg88Trp | p.R88W | Q15527 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SURF2 | SNV | Missense_Mutation | novel | c.313N>T | p.Arg105Trp | p.R105W | Q15527 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
SURF2 | SNV | Missense_Mutation | c.608N>C | p.Lys203Thr | p.K203T | Q15527 | protein_coding | tolerated(0.07) | benign(0.009) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
SURF2 | SNV | Missense_Mutation | novel | c.626N>T | p.Ala209Val | p.A209V | Q15527 | protein_coding | tolerated(0.06) | benign(0.009) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
SURF2 | SNV | Missense_Mutation | novel | c.323N>A | p.Arg108Gln | p.R108Q | Q15527 | protein_coding | deleterious(0.01) | possibly_damaging(0.814) | TCGA-EY-A1G8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SURF2 | SNV | Missense_Mutation | rs781901962 | c.434N>A | p.Arg145His | p.R145H | Q15527 | protein_coding | tolerated(0.65) | benign(0.005) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |